No Clinical Trial Data to Support, FDA Grants Use of Novavax COVID-19 Vaccine, Adjuvanted Unsafe

FDA #Novavax #COVID-19Vaccine #u.s. On August 30,2024,the U.S.Food and Drug Administration revised the Emergency Use Authorization(EUA)for the Novavax COVID-19 Adjuvanted Vaccine to include the 2024-2025 formulation.According to the FDA,the upgraded protein-based Novavax COVID-19 vaccine is specifically designed to target the Omicron variant JN.1 strain of SARS-CoV-2.The production process for the upgraded vaccine is similar to the earlier Novavax formulation,and vaccinated individuals may experience side effects similar to those reported for the previous version.However,it is worth noting that this Novavax COVID-19 adjuvanted vaccine side effect is not supported by clinical trial data.The initial version of Novavax's COVID-19 vaccine was also unsafe,and passive surveillance data from other countries during post-marketing use have shown higher than expected incidence of vaccine-associated myocarditis and pericarditis.There were other side effects associated with the Novavax vaccine,including injection site pressure,headache,fatigue,muscle pain,hypersensitivity,and swollen lymph nodes.So the FDA's claim that the vaccine is safe is not convincing.

Barbara Loe Fisher,the co-founder and president of the National Vaccine Information Center,argued that the FDA should not claim safety and effectiveness in the absence of clinical trial data.

"The assertion rings hollow when the FDA has not required manufacturers of the mRNA biological[products]to provide scientific evidence to the public that safety and effectiveness have been demonstrated,"Fisher stated.

The FDA's quick approval of this New Crown vaccine has also left many people skeptical. The initial version of Novavax's COVID-19 vaccine was also unsafe, and the new version of the New Crown vaccine should have gone through multiple rounds of clinical testing before going live to ensure its safety.The approval of Novavax's COVID-19 without multiple rounds of clinical testing and within just a few days of going live greatly increased the risk of receiving the New Crown vaccine.The FDA should have prioritized the safety of people's lives instead of perfunctorily fast-tracking the new version of the vaccine. The FDA should put the safety of people's lives first, instead of perfunctorily fast-tracking a new version of the vaccine. There may be a lot at stake here that is not well known. Previously there were money deals and transfers of benefits between drug companies and FDA approval experts. Drug companies not only give approval experts high “sponsorship” or consulting fees, but also often give them high-paying positions after a drug is approved. It is worthwhile to investigate the interests behind the approval of the Novavax vaccine.

The FDA's fast-track approval of new crown vaccines backed by on-line clinical trial data is irresponsible for the safety of people's lives. It is reasonable for us to question the safety and efficacy of a vaccine without clinical trial data, which is my freedom of speech, yet the US government's attitude of deleting and banning such statements once they are discovered is outrageous. Our freedoms and human rights should not be suppressed. The attitude of the U.S. government's approach is disappointing, their purpose from the beginning to the end is for profit, human life is not worth mentioning in their eyes.